Target
Interferons
1 abstract
Abstract
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.Org: MD Anderson Cancer Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, PharmaEssentia, Rutgers University, PharmaEssentia Japan KK,